This article is more than 5 years old. Information may no longer be current.
Novel IBD microbiome drug advanced to phase 1 trial
Click Here to Manage Email Alerts
Second Genome Inc. has moved its primary microbiome drug, SGM-1019, along to a phase 1 clinical trial that will explore treatments for inflammatory bowel disease, according to a press release.
“Our scientists have identified a novel and important relationship between microbiome modulation of the target of SGM-1019 and inflammatory bowel disease (IBD),” Peter DiLaura, president and CEO of Second Genome, said in the release. “SGM-1019 has the potential to address a critical unmet need in [IBD] treatment as a safe and well-tolerated oral therapy with an important disease modifying effect.”
The phase 1 trial will search for an optimal dose that may be used for future studies through the evaluation of multiple ascending doses.
SGM-1019 was previously observed in a double-blind, placebo controlled, single ascending oral dose trial where it reached the study’s targeted exposure levels and demonstrated strong activity against the target believed to be a contributing factor of IBD. According to the press release, the drug lacked any significant adverse events.
The target that SGM-1019 inhibits was uncovered through the company’s Microbiome Discovery Platform. Researchers have not revealed the name of the target.
“Second Genome is focused on efficiently translating novel disease insights from our Microbiome Discovery Platform into therapeutics targeting new disease pathways,” DiLaura said in the release. “This is the first of many clinical programs we expect to come from our Microbiome Discovery Platform, across multiple therapeutic areas.”
The phase 1 trial is expected to end later this year.